

Summary of Lothian Joint Formulary Amendments

The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The website chapters should be referred to for full details. The month indicates when Formulary Committee approved the changes.

March 2020

Chapter 1 Gastro-intestinal System - Adults

Plenvu[®] (macrogol 3350 with anhydrous sodium sulfate, ascorbic acid, potassium chloride, sodium ascorbate, sodium chloride) is now routinely available in line with local guidance. It is now included on the Additional List for Specialist Use only, and has been added to the LJF webtable as an alternative option to Moviprep[®] for bowel cleansing in adults.

Chapter 6 Endocrine – Adults

6.1.1 Insulins

- The general notes have been updated to remove Insuman Comb 15 (recombinant human insulin - insulin isophane human 85 unit per 1 mL / insulin soluble human 15 unit per 1 mL), which is being discontinued.

6.4.2 male sex hormones

- testosterone gel (Tostran[®]) is now an alternative first choice to testosterone injection (Nebido[®]). Tostran was previously second choice. Both Tostran and Nebido[®] should be initiated on specialist advice.

Chapter 10 Musculoskeletal and Joint Diseases - Adults

10.3 Topical NSAIDs

- ibuprofen 5% gel is now the first choice topical NSAID as it is the most cost effective option.

Chapter 12 Ear, Nose and Oropharynx – Adults

12.3.2 Oropharyngeal anti-infective drugs

- The dose recommendations for miconazole and nystatin have been aligned with the doses in LJF section 5.0 (h) Infections / ENT.
- The prescribing note on good denture care has been updated. Nystatin is no longer recommended as a denture soak for the duration of treatment.

Chapter 13 Skin – Adults

13.8.1.1 Actinic keratosis

- ingenol mebutate gel (Picato[®]) has been removed as the second choice. This follows the suspension of its marketing authorization and stock recall in January 2020. The first choices remain diclofenac gel 3% (Solaraze[®]) or fluoruracil (Efudix[®]).

Chapter 3 Respiratory System – Children

3.1.3 Theophylline preparations

- The theophylline brand of choice has been changed to Uniphyllin Continus[®] prolonged release tablets, which replaces Slo Phyllin[®] capsules. Prescribers are referred to the BNFc for dosing. Several new prescribing notes have been added.

Chapter 4 Central Nervous System – Children

4.7 Analgesics, General management of pain

- ibuprofen oral suspension 100mg/5mL has replaced ibuprofen syrup 100mg/5mL.

4.7.4.1 Antimigraine drugs, Treatment of the acute attack

- ibuprofen 600mg tablets have been removed.
- ibuprofen oral suspension 100mg/5mL has replaced ibuprofen syrup 100mg/5mL.